Sphingomyelinase inhibitors, such asperphenazine and fluphenazine – classified as functionalinhibitors of acidic sphingomyelinase (FIASMA) – showpotential in cancer therapy, though further studies are neededto validate their efficacy (Kornhuber et al., 2010). Here, SMPD1 is linked to cancer.